Effect of bevacizumab on refractory meningiomas: 3D volumetric growth rate versus response assessment in neuro-oncology criteria.

ABSTRACT:

Background

Meningiomas are the most common primary tumor in the central nervous system. About 15%-20% are aggressive and tend to recur and progress despite conventional treatment. Bevacizumab has been found to be effective in the treatment of refractory meningiomas in retrospective studies. The Response Assessment in Neuro-Oncology (RANO) criteria are widely used to assess the effect of treatment. Recent studies suggest that the 3D volumetric growth rate (3DVGR) may be more accurate for irregularly shaped tumors. The aim of this study was to compare these approaches.

Methods

Twenty patients with refractory meningiomas were treated with bevacizumab. Tumors were measured using the RANO criteria and 3DVGR before and after initiation of treatment by 2 radiologists using PACS and

SUBMITTER: Faye Borenstein S 

PROVIDER: S-EPMC11520742 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature